Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2019 2020 2021 2022 2023 2024 2025
Months
January February March April May June July August September October November December
Previous Archive
25 November 2020 Photo Anja Aucamp
Prof Colin Chasi outside Centenary Complex (Anja Aucamp)
Prof Colin Chasi is the Director of the Unit for Institutional Change and Social Justice at the UFS.
The 2020 programme around the 16 Days of Activism against Gender-Based Violence will be novel in that it will be run online. “For each person to register and log into the various programmes is a small step. But each such step makes a big difference by saying that the lives of survivors matter and by underscoring that gender-based violence will not be tolerated at the UFS,” says Prof Colin Chasi, Director of the Unit for Institutional Change and Social Justice (UICSJ) at the UFS.

Women and girl children have experienced increased violence in the time of the COVID-19 lockdown, states the UN Secretary General's report, Shared Responsibility, Global Solidarity: Responding to the socio-economic impacts of COVID-19. In South Africa, there have been reports of a scourge of rape in the post-school education and training sector. At the UFS, these developments have challenged the Gender Equity and Anti-Discrimination Office (GEADO) to come up with innovative online interventions.

In 2019, the University of the Free State (UFS) established the Unit for Institutional Change and Social Justice (formerly known as the Institute for Reconciliation and Social Justice, founded in 2009). The GEADO was launched on 8 April 2019 and was incorporated into the unit to run a cross-functional Sexual Assault Response Team (SART) and to organise programmes that combat gender-based violence and other forms of gender injustice.

“We have been able to offer our services with minimal disruption throughout the year,” says Geraldine Lengau, a Bloemfontein Campus-based GEADO officer.

“Most exciting for us is that we have taken the lockdown as an opportunity to expand the scope of ways in which we engage with students and communities,” notes Chelepe Mocwana, a GEADO officer on the South Campus. “GEADO has offered a number of online webinars and seminars, and the university has made telephonic services available that support, for example, the mental health of survivors of sexual violence.”

“On the Qwaqwa Campus, where we still have some problems with consistent access to data networks, we were pleased to see that our webinars have been well-subscribed to by students and staff members,” reports Siya Magayana, who is the GEADO officer on this campus.

“Each such step makes a big difference by saying that the
lives of survivors matter and by underscoring that
gender-based violence will not be tolerated at the UFS.”
—Prof Colin Chasi, Director of the UICSJ.

Since 1991, activists around the world have annually coordinated activities around the 16 Days of Activism against Gender-Based Violence. The 16 days of activism begin on 25 November, the International Day for the Elimination of Violence against Women, and run until 10 December, which is International Human Rights Day. The start and end dates signify that the fight to eliminate violence against women advances human rights for all.

Activities to mark the 16 Days of Activism against Gender-Based Violence will be advertised on various UFS communication platforms.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept